Randomised controlled trials evaluating anticancer therapies in haematological cancers: an overview of global research activity.

Manju Sengar,Wilma M Hopman,Ghulam Rehman Mohyuddin,Aaron M Goodman,Bishal Gyawali,Deborah Mukherji,Nazik Hammad,C S Pramesh,Ajay Aggarwal,Richard Sullivan,Christopher M Booth

Ecancermedicalscience（2023）

引用 0|浏览12

暂无评分

摘要

The fact that only 12% of haematological cancer RCTs are designed to show improvements in OS is of grave concern for the field and the care of future patients. This is further compounded by the highly prevalent use of alternative primary endpoints that are rarely valid surrogates for OS in haematological cancers.

查看译文

关键词

randomised controlled trials, haematological cancers, endpoints

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要